MSD Fined €39m In Spain Over Blocking Nuvaring Rival
Insud Pharma’s Ornibel Version Suffered Following Originator Abuse Of Dominant Position
Executive Summary
Spanish competition regulator the CNMC has fined Merck Sharp and Dohme €39m for abusing its dominant position, by blocking Insud Pharma’s rival to the Nuvaring vaginal contraceptive ring through “unjustified legal action” that sought to delay market entry of Insud’s Ornibel version. The originator is considering an appeal.
You may also be interested in...
European Commission Targets Teva Over Alleged Copaxone Antitrust Breach
A European Commission investigation into Teva’s conduct over its Copaxone multiple sclerosis drug has led to the firm receiving a statement of objections, which details a preliminary finding that the company violated EU antitrust laws.
EU Commission Targets Teva Over Alleged Copaxone Antitrust Breach
A 2021 investigation into Teva’s conduct over its Copaxone multiple sclerosis drug by the European Commission has led to the firm receiving a statement of objections, which details a preliminary finding that the company violated EU antitrust laws.
Fixing The UK Market: Government Must Move From ‘Transactional’ To ‘Strategic’ Approach
With the UK market experiencing approval delays, shortages, and regulatory complexity, the government’s “policy vacuum” and complacent approach to off-patent medicines risk undermining the sector, says BGMA chair Diane DiGangi Trench. In an exclusive interview with Generics Bulletin, she urges a shift from a “transactional” to a “strategic” relationship with industry to fully unlock the benefits of generics and biosimilars.